Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Gene expression microarrays as a prognostic test

William E Evans1

  • 1St. Jude Children's Research Hospital, USA.

Clinical Advances in Hematology & Oncology : H&O
|March 25, 2006
PubMed
Summary

No abstract available in PubMed .

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Somatic mtDNA mutations at intermediate levels of heteroplasmy are a source of functional heterogeneity among primary leukemic cells.

Science advances·2025
Same author

Differentiation-dependent EBF1 activity determines CD22 transcription and leukemia sensitivity to inotuzumab ozogamicin.

Blood·2025
Same author

Molecular and pharmacological heterogeneity of ETV6::RUNX1 acute lymphoblastic leukemia.

Nature communications·2025
Same author

DNTT-mediated DNA damage response drives inotuzumab ozogamicin resistance in B-cell acute lymphoblastic leukemia.

Blood·2025
Same author

Pharmacogenomics in Pediatric Oncology Research and Treatment.

The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG·2024
Same author

Impact of Age on Pharmacogenomics and Treatment Outcomes of B-Cell Acute Lymphoblastic Leukemia.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2024
Same journal

Clinical response with cabozantinib plus nivolumab, a first-line therapy in advanced renal cell carcinoma: a clinical case report.

Clinical advances in hematology & oncology : H&O·2026
Same journal

Active treatment in high-risk, early-stage CLL or SLL.

Clinical advances in hematology & oncology : H&O·2026
Same journal

Targeting human kallikrein 2 in prostate cancer.

Clinical advances in hematology & oncology : H&O·2026
Same journal

Targeting BRAF V600E mutations in metastatic colorectal cancer.

Clinical advances in hematology & oncology : H&O·2026
Same journal

The development of second-generation KRAS inhibitors.

Clinical advances in hematology & oncology : H&O·2026
Same journal

Clinical applications of PARP inhibitors in breast, ovarian, and prostate cancer: current insights and future directions.

Clinical advances in hematology & oncology : H&O·2026
See all related articles